SK-OV-3

SK-OV-3是一種二倍體卵巢癌細胞系，最初在1973年分離自一名64歲白人女性囊腺癌患者的腹水^[1]。在63.3％的SK-OV-3細胞中，染色體的模態數為43，而範圍則為42至45。 SK-OV-3對許多用於鑑定上皮來源癌的抗原，呈陽性反應，包括波形蛋白、高分子量細胞角蛋白（英語：Cytokeratin）、低分子量細胞角蛋白、上皮膜抗原（epithelial membrane antigen）和蛋白酪氨酸磷酸酶C型受體^[2]。早期的研究報告指出，SK-OV-3細胞不會表達CA-125（一種細胞表面抗原），而該抗原後來成為檢測卵巢癌最常用的生物標誌物，並且通過劑量反應曲線（英語：Dose–response relationship）表明SK-OV-3細胞對鉑敏感^[3]^[4]。隨後的研究更顯示，SK-OV-3細胞中CA-125 C末端結構域的異位表達，降低了其對順鉑誘導的細胞凋亡的敏感性^[5]。目前已經有研究指出其具有中度分化能力，將SK-OV-3注入裸鼠後，裸鼠體內會產生大的實體腫瘤，並且會鬆散地附著在骨盆區域、腸或大網膜（英語：Greater omentum）的脂肪上^[2]。

[1]
Fogh, J; Fogh, JM; Orfeo, T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.. Journal of the National Cancer Institute. 1977-07, 59 (1): 221–6 [2020-01-17]. PMID 327080. doi:10.1093/jnci/59.1.221. （原始內容存檔於2020-01-12）.
[2]
Shaw, TJ; Senterman, MK; Dawson, K; Crane, CA; Vanderhyden, BC. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer.. Molecular therapy : the journal of the American Society of Gene Therapy. 2004-12, 10 (6): 1032–42 [2020-01-17]. PMID 15564135. doi:10.1016/j.ymthe.2004.08.013.^{[永久失效連結]}
[3]
Fogh, J. Human tumor lines for cancer research.. Cancer investigation. 1986, 4 (2): 157–84 [2020-01-17]. PMID 3518877. doi:10.3109/07357908609038260.^{[永久失效連結]}
[4]
Suh, KS; Park, SW; Castro, A; Patel, H; Blake, P; Liang, M; Goy, A. Ovarian cancer biomarkers for molecular biosensors and translational medicine.. Expert review of molecular diagnostics. 2010-11, 10 (8): 1069–83 [2020-01-17]. PMID 21080822. doi:10.1586/erm.10.87.^{[永久失效連結]}
[5]
Boivin, M; Lane, D; Piché, A; Rancourt, C. CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.. Gynecologic oncology. 2009-12, 115 (3): 407–13 [2020-01-17]. PMID 19747716. doi:10.1016/j.ygyno.2009.08.007.^{[永久失效連結]}

Remove ads

Cellosaurus entry for SK-OV-3（頁面存檔備份，存於網際網路檔案館）

[1] [1]
Fogh, J; Fogh, JM; Orfeo, T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.. Journal of the National Cancer Institute. 1977-07, 59 (1): 221–6 [2020-01-17]. PMID 327080. doi:10.1093/jnci/59.1.221. （原始內容存檔於2020-01-12）.

[a-2] [2]
Shaw, TJ; Senterman, MK; Dawson, K; Crane, CA; Vanderhyden, BC. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer.. Molecular therapy : the journal of the American Society of Gene Therapy. 2004-12, 10 (6): 1032–42 [2020-01-17]. PMID 15564135. doi:10.1016/j.ymthe.2004.08.013.^{[永久失效連結]}

[3] [3]
Fogh, J. Human tumor lines for cancer research.. Cancer investigation. 1986, 4 (2): 157–84 [2020-01-17]. PMID 3518877. doi:10.3109/07357908609038260.^{[永久失效連結]}

[4] [4]
Suh, KS; Park, SW; Castro, A; Patel, H; Blake, P; Liang, M; Goy, A. Ovarian cancer biomarkers for molecular biosensors and translational medicine.. Expert review of molecular diagnostics. 2010-11, 10 (8): 1069–83 [2020-01-17]. PMID 21080822. doi:10.1586/erm.10.87.^{[永久失效連結]}

[5] [5]
Boivin, M; Lane, D; Piché, A; Rancourt, C. CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.. Gynecologic oncology. 2009-12, 115 (3): 407–13 [2020-01-17]. PMID 19747716. doi:10.1016/j.ygyno.2009.08.007.^{[永久失效連結]}

[1]

[2]

[3]

[4]

[5]

SK-OV-3

Wikiwand in your browser!

SK-OV-3

Wikiwand in your browser!

參考資料

外部連結